Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Tratamiento farmacológico a largo plazo para la obesidad y el sobrepeso

Información

DOI:
https://doi.org/10.1002/14651858.CD004094.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 20 octubre 2003see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Trastornos metabólicos y endocrinos

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Raj S Padwal

    Correspondencia a: 2E3.22 WMHSC, University of Alberta Hospital, Edmonton, AB, Canada

    [email protected]

  • Diana Rucker

    Internal Medicine , University of Alberta, Edmonton, AB, Canada

  • Stephanie K Li

    Internal Medicine (PGY4), University of Alberta , Edmonton, AB, Canada

  • Cintia Curioni

    Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

  • David CW Lau

    Department of Medicine, University of Calgary, Calgary, Canada

Contributions of authors

RAJ PADWAL: registered the topic, performed the literature search and collected articles, reviewed articles for inclusion and methodological quality, performed data entry and statistical calculations, and was the primary author for the initial and final drafts.

DIANA RUCKER: performed the literature search for the update, collected articles, reviewed articles for inclusion and quality, performed data entry and statistical calculations and co‐authored the update.

STEPHANIE LI: collected articles, reviewed articles for inclusion and methodological quality, performed data entry and co‐wrote the final draft.

CINTIA CURIONI and DAVID LAU: co‐designed the review, provided expert advice and co‐wrote the initial and final drafts.

Sources of support

Internal sources

  • Department of Medicine, University of Alberta, Canada.

External sources

  • No sources of support supplied

Declarations of interest

R. Padwal: none known.
D. Rucker: none known.
S. Li: none known.
C.Curioni: none known.
D. Lau: David Lau owns common shares in GlaxoSmithKline and Eli Lilly. He is a consultant to Abbott Laboratories, Ltd., AstraZeneca Canada Inc., Merck Frosst Canada
Inc., Bristol‐Myers Squibb Canada, Eli Lilly Canada Inc., Oryx Pharmaceuticals Inc., Pfizer Canada Inc., sanofi‐aventis Canada Inc., Servier Canada Inc. and Solvay Pharma Inc.; and has received speaker fees from Abbott Laboratories, Ltd., AstraZeneca Canada Inc., GlaxoSmithKline, Merck Frosst Canada Inc., Merck/Schering, Eli Lilly Canada Inc., sanofi‐aventis Canada Inc. and Novo Nordisk Canada Inc.; research grants from AstraZeneca Canada Inc., Bristol Myers Squibb, Dainippon Pharmaceuticals, GlaxoSmithKline, Pfizer Canada Inc., and Sanofi‐Aventis Canada Inc.; and travel assistance to attend international meetings from Abbott Laboratories, Ltd., AstraZeneca Canada Inc. and Sanofi‐Aventis Canada Inc.

Acknowledgements

The authors would like to acknowledge the help of Ms. Jeannette Buckingham in helping to update our search and to study authors who provided supplemental data.

Version history

Published

Title

Stage

Authors

Version

2003 Oct 20

Long‐term pharmacotherapy for obesity and overweight

Review

Raj S Padwal, Diana Rucker, Stephanie K Li, Cintia Curioni, David CW Lau

https://doi.org/10.1002/14651858.CD004094.pub2

2002 Jul 22

Long‐term pharmacotherapy for obesity

Protocol

Raj S Padwal, David CW Lau, Stephanie K Li, Susan L Norris

https://doi.org/10.1002/14651858.CD004094